While the presence of FMRP production prevents the manifestation of FXS phenotypes, the RNA toxicity due to elevated levels of FMR1 mRNA (Table 1) may contribute to increased baseline oxidative stress and mitochondrial toxicity, leading to clinical findings associated with the premutation. This evidence concerns the gene FMR1 and fragile X syndrome.